- Led by Edmond Knopp, MD, VP of Medical Affairs - Welcoming three KOLs to discuss clinical developments in ultra-low-field…
Oakville, Ontario--(Newsfile Corp. - June 3, 2024) - Psirenity Health is incredibly pleased to announce that Mr. Andrew Macdonald has…
HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced…
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024HOUSTON, TX, June 03, 2024 (GLOBE…
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular…
Scope of the SESHAT Project at Pioneering Hospital, Part of the Catalan Health Institute, Includes Deployment of up to 1,000…
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and…
Newly Launched Technology Will Be on Display at ASSFN in Nashville from June 1 - 4 ClearPoint Neuro Announces Full…
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon…